ArrowMark Colorado Holdings LLC Sells 80,046 Shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO)

ArrowMark Colorado Holdings LLC lessened its position in Halozyme Therapeutics, Inc. (NASDAQ:HALO) by 3.8% in the 3rd quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 2,010,655 shares of the biopharmaceutical company’s stock after selling 80,046 shares during the period. Halozyme Therapeutics makes up about 1.5% of ArrowMark Colorado Holdings LLC’s investment portfolio, making the stock its 17th biggest holding. ArrowMark Colorado Holdings LLC’s holdings in Halozyme Therapeutics were worth $115,090,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently made changes to their positions in HALO. Boston Trust Walden Corp bought a new position in shares of Halozyme Therapeutics during the 2nd quarter valued at about $23,211,000. Segall Bryant & Hamill LLC raised its holdings in shares of Halozyme Therapeutics by 16.3% during the third quarter. Segall Bryant & Hamill LLC now owns 355,176 shares of the biopharmaceutical company’s stock worth $20,330,000 after acquiring an additional 49,856 shares during the period. Creative Planning lifted its position in Halozyme Therapeutics by 43.2% in the 2nd quarter. Creative Planning now owns 37,291 shares of the biopharmaceutical company’s stock valued at $1,953,000 after acquiring an additional 11,249 shares in the last quarter. South Street Advisors LLC acquired a new position in Halozyme Therapeutics in the 3rd quarter worth $9,812,000. Finally, RPg Family Wealth Advisory LLC bought a new stake in Halozyme Therapeutics in the 3rd quarter valued at approximately $1,886,000. 97.79% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

HALO has been the topic of a number of research reports. Benchmark reissued a “buy” rating and issued a $60.00 price objective on shares of Halozyme Therapeutics in a research report on Thursday, August 8th. JPMorgan Chase & Co. cut Halozyme Therapeutics from an “overweight” rating to a “neutral” rating and increased their price target for the company from $52.00 to $57.00 in a research report on Thursday, September 19th. HC Wainwright reaffirmed a “buy” rating and set a $68.00 price target on shares of Halozyme Therapeutics in a research report on Wednesday, November 20th. JMP Securities raised their target price on shares of Halozyme Therapeutics from $72.00 to $73.00 and gave the company a “market outperform” rating in a research note on Friday, November 1st. Finally, Piper Sandler upped their price target on shares of Halozyme Therapeutics from $51.00 to $52.00 and gave the stock a “neutral” rating in a research report on Monday, November 4th. Four equities research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company. According to data from MarketBeat, Halozyme Therapeutics has a consensus rating of “Moderate Buy” and a consensus target price of $61.11.

Insider Activity at Halozyme Therapeutics

In related news, SVP Michael J. Labarre sold 10,000 shares of the business’s stock in a transaction that occurred on Wednesday, October 16th. The stock was sold at an average price of $53.26, for a total value of $532,600.00. Following the completion of the sale, the senior vice president now directly owns 173,756 shares in the company, valued at approximately $9,254,244.56. The trade was a 5.44 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through this link. Over the last three months, insiders have sold 60,000 shares of company stock worth $3,425,000. Corporate insiders own 2.40% of the company’s stock.

Halozyme Therapeutics Stock Performance

Shares of NASDAQ HALO opened at $48.20 on Monday. Halozyme Therapeutics, Inc. has a one year low of $33.15 and a one year high of $65.53. The company has a debt-to-equity ratio of 3.32, a current ratio of 10.36 and a quick ratio of 9.15. The firm has a market cap of $6.13 billion, a price-to-earnings ratio of 15.96, a P/E/G ratio of 0.44 and a beta of 1.29. The stock’s fifty day moving average price is $53.28 and its two-hundred day moving average price is $53.79.

Halozyme Therapeutics Profile

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.